Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population.
CVD
MAFLD
NAFLD
fibroscan and transient elastography
fibrosis
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
05
2021
accepted:
12
07
2021
entrez:
12
8
2021
pubmed:
13
8
2021
medline:
12
2
2022
Statut:
epublish
Résumé
Cardiovascular disease (CVD) risk is higher in patients with nonalcoholic fatty liver disease (NAFLD). To evaluate whether this can be attributed to the link between NAFLD and known CVD risk factors or to an independent contribution of liver steatosis and fibrosis. This is an analysis of data from the 2017-2018 cycle of the National Health and Nutrition Examination Survey. We included participants older than 40 years with available data on vibration-controlled transient elastography (VCTE) and without viral hepatitis and significant alcohol consumption. Steatosis and fibrosis were diagnosed by the median value of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), respectively. History of CVD was self-reported and defined as a composite of coronary artery disease and stroke/transient ischemic attacks. Among the 2734 included participants, prevalence of NAFLD was 48.6% (95% CI 45.1-51.4), 316 participants (9.7%, 95% CI 8.1-11.6) had evidence of significant liver fibrosis and 371 (11.5%, 95% CI 9.5-13.9) had a history of CVD. In univariate analysis, patients with CVD had a higher prevalence of steatosis (59.6% In this population-based study, we did not identify an independent association between steatosis and fibrosis and CVD. Large prospective cohort studies are needed to provide a more definitive evidence on this topic.
Sections du résumé
Background
Cardiovascular disease (CVD) risk is higher in patients with nonalcoholic fatty liver disease (NAFLD).
Aim
To evaluate whether this can be attributed to the link between NAFLD and known CVD risk factors or to an independent contribution of liver steatosis and fibrosis.
Methods
This is an analysis of data from the 2017-2018 cycle of the National Health and Nutrition Examination Survey. We included participants older than 40 years with available data on vibration-controlled transient elastography (VCTE) and without viral hepatitis and significant alcohol consumption. Steatosis and fibrosis were diagnosed by the median value of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), respectively. History of CVD was self-reported and defined as a composite of coronary artery disease and stroke/transient ischemic attacks.
Results
Among the 2734 included participants, prevalence of NAFLD was 48.6% (95% CI 45.1-51.4), 316 participants (9.7%, 95% CI 8.1-11.6) had evidence of significant liver fibrosis and 371 (11.5%, 95% CI 9.5-13.9) had a history of CVD. In univariate analysis, patients with CVD had a higher prevalence of steatosis (59.6%
Conclusions
In this population-based study, we did not identify an independent association between steatosis and fibrosis and CVD. Large prospective cohort studies are needed to provide a more definitive evidence on this topic.
Identifiants
pubmed: 34381424
doi: 10.3389/fendo.2021.711484
pmc: PMC8350483
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
711484Informations de copyright
Copyright © 2021 Ciardullo, Cannistraci, Mazzetti, Mortara and Perseghin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Gastroenterol Hepatol. 2021 Feb;19(2):384-390.e1
pubmed: 32623006
Hypertension. 2020 Aug;76(2):562-568
pubmed: 32594797
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
BMJ. 2019 Oct 8;367:l5367
pubmed: 31594780
Aliment Pharmacol Ther. 2020 Apr;51(7):728-736
pubmed: 32043602
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Diabetologia. 2008 Nov;51(11):1947-53
pubmed: 18762907
JHEP Rep. 2020 Dec 05;3(2):100219
pubmed: 33659890
J Hepatol. 2010 Feb;52(2):206-10
pubmed: 20022130
Radiology. 2010 Dec;257(3):872-8
pubmed: 20935077
Diabetes Care. 2021 Feb;44(2):519-525
pubmed: 33303638
Liver Int. 2019 Jan;39(1):197-204
pubmed: 30253056
Gastroenterology. 2019 Apr;156(5):1264-1281.e4
pubmed: 30660725
Hepatology. 2021 Feb;73(2):548-559
pubmed: 33125745
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
N Engl J Med. 2010 Sep 30;363(14):1341-50
pubmed: 20879883
Hepatology. 2020 Nov;72(5):1605-1616
pubmed: 32043613
J Hepatol. 2016 Sep;65(3):589-600
pubmed: 27212244
Hepatology. 2009 Mar;49(3):1017-44
pubmed: 19243014
Am J Med. 1999 Nov;107(5):450-5
pubmed: 10569299
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Am J Gastroenterol. 1999 Sep;94(9):2467-74
pubmed: 10484010
Gut. 2011 Jul;60(7):977-84
pubmed: 21068129
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Gastroenterology. 2019 May;156(6):1717-1730
pubmed: 30689971
Gut. 2020 Jul;69(7):1343-1352
pubmed: 32066623